Tiziana Life Sciences Financials - Benzinga

SPY772.04+0.09%QQQ745.40+0.12%BTC/USD83,815.17−0.74%DIA517.72+0.04%GLD393.05−0.09%TLT79.38+0.08%

Tiziana Life Sciences Ltd

TLSANASDAQ

Trade with Public

Trade with Public

$1.01

-0.03-2.88%

At close: Sep 25, 5:00 PM EST

$1.04

0.032.97%

After Hours: Sep 25, 9:26 AM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Tiziana Life Sciences Financials

Tiziana Life Sciences (TLSA) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Why Las Vegas Sands Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Avi Kapoor

Tiziana Life Sciences Ltd Reports Annual Results For The 12 Months Ended December 31, 2022, And Corporate Update; Tiziana Ended The Period With $18.1M Cash

2022 Year End Financial Results For the twelve months ended 31 December 2022 Tiziana reported a loss of $19.0 million compared to $27.9 million in the twelve months ended 31 December

Happy Mohamed

PRO
Tiziana Life Sciences 1H Net Loss $8.3M

Benzinga Newsdesk

PRO
UPDATE: Tiziana Sees Clinical Trial For Crohn's Disease Candidate In Q4'22

Benzinga Newsdesk

The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29)

Shanthi Rexaline

The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1)

Shanthi Rexaline

© 2026 Benzinga | All Rights Reserved